Holen Sie sich die Stockscreener-App
1.32
1.49%
-0.02
Vorhandelsmarkt:
1.60
0.28
+21.21%
Schlusskurs vom Vortag:
$1.34
Offen:
$1.37
24-Stunden-Volumen:
269.66K
Relative Volume:
0.83
Marktkapitalisierung:
$127.94M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-0.4475
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
+2.33%
1M Leistung:
+8.20%
6M Leistung:
-53.19%
1J Leistung:
-68.50%
1-Tages-Spanne:
$1.2543
$1.37
1-Wochen-Bereich:
$1.225
$1.37
52-Wochen-Spanne:
$1.05
$4.32
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.32 | 127.94M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics Reports First Quarter 2025 Financial Results - TradingView
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update - PR Newswire
ADC Therapeutics reports high response in lymphoma trial - Investing.com
Breakthrough: New Cancer Drug Combo ZYNLONTA-COLUMVI Achieves 90% Complete Response in Lymphoma Trial - Stock Titan
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Barclays PLC Purchases 13,756 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 - BioSpace
JPMorgan Chase & Co. Has $74,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday - Defense World
LPL Financial LLC Invests $50,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
BlackRock, Inc. Reduces Stake in ADC Therapeutics SA - GuruFocus
Geode Capital Management LLC Acquires 9,938 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data a - GuruFocus
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - BioSpace
Stock Market Recap: Adc Therapeutics SA (ADCT) Concludes at 1.41, a -5.37 Surge/Decline - DWinneX
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ADC Therapeutics Announces Preclinical Data Highlighted at the A - GuruFocus
ADC Therapeutics (ADCT) Unveils Promising Preclinical ADC Data at AACR 2025 | ADCT Stock News - GuruFocus
Russell Investments Group Ltd. Buys 9,248 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Seeking Alpha
Antibody Drug Conjugate Market to Witness Upsurge in Growth - openPR.com
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting - marketscreener.com
Sei Investments Co. Invests $46,000 in ADC Therapeutics SA (NYSE:ADCT) - The AM Reporter
Sei Investments Co. Makes New $46,000 Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Prudential Financial Inc. Invests $35,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Neuroendocrine tumors Pipeline Analysis and Clinical Trials - openPR.com
SEC Form PRE 14A filed by ADC Therapeutics SA - Quantisnow
HC Wainwright Lifts Earnings Estimates for ADC Therapeutics - MarketBeat
ADC Therapeutics : 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
Analyzing Ratios: Adc Therapeutics SA (ADCT)’s Financial Story Unveiled - DWinneX
ADC Therapeutics SA (NYSE:ADCT) Sees Large Decline in Short Interest - MarketBeat
Research Analysts Set Expectations for ADCT Q1 Earnings - Defense World
Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight - The Globe and Mail
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
NBE Therapeutics opens ADC research facility in Switzerland - Pharmaceutical Technology
ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
ADC Therapeutics (NYSE:ADCT) Given New $7.00 Price Target at Guggenheim - MarketBeat
ADCT Stock Touches 52-Week Low at $1.61 Amid Market Challenges - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Bradford Era
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):